|
|
 |
|
Viewing report
|
|
|
|
U.S. Colorectal Cancer Market
Frost & Sullivan, Dec 2009, Pages: 81
This research service provides the market overview, market trends, patient and revenue forecasts for colorectal cancer in the U.S. from 2006-2016. The patient population and revenue forecasts are discussed in terms of staging and line of therapy. This includes in-depth analysis of the market segmented by line of therapy providing competitive information and pipeline analysis. This research service also captures results from the Frost & Sullivan 'Voice of the Customer' analysis of drug delivery in oncology. This research service serves as an update to F205-52 on the U.S. colorectal cancer market published in 2005-06.
This Frost & Sullivan research service titled U.S. Colorectal Cancer Market provides an extensive analysis of the colon and rectal cancer markets including therapeutic segment analysis, patient, market share analysis, and industry challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: adjuvant therapies, first-line therapies, and second- and third-line therapies.
Market Overview
Strong Pipeline Attracts the Big Pharma to the Colorectal Cancer Market
The lack of a successful adjuvant therapy to cater to a new class of patients is restricting any potential expansion growth of the colorectal cancer market. However, the strong clinical pipeline, large unmet medical needs, and considerable interest from across the tiers, especially the Big Pharma companies, are setting the stage for greater penetration of colorectal cancer therapies within existing segments. “In addition to targeted therapies and cytotoxics, market participants need to focus on improving the quality of adjuvant therapies,” says the analyst of this research. “This segment has historically been driven by the inexpensive 5-fluororacil (5-FU), but recently there has been a shift toward more expensive therapies with the expansion of targeted therapies in the first, second, and third-line therapy markets.”
So far, pharmaceutical and biotechnology companies have failed to develop an adjuvant therapy for stage II patients. This has restricted market expansion, since this stage represents the largest segment of colorectal cancer patients without any access to a drug that can reduce the risk of recurrence. Although several drugs are currently in trials, none has made it to the final stages of product development. The failure of the hugely successful first-line drug Avastin (bevacizumab) in phase III trials for use as an adjuvant therapy in combination with FOLFOX further illustrates the complexity of this challenge. “Despite the challenges faced, the strong clinical pipeline comprising of combination therapies as well as new candidates augurs well for the market,” notes the analyst. “As more patients are being diagnosed through better screening and increased penetration of the approved therapies, the market is further stabilizing and attracting greater attention from across tiers of the pharmaceutical and biotechnology industries.”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Adjuvant therapies
- First-line therapies
- Second and third-line therapies
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Drug Delivery in Cancer - Technologies, Markets and Companies
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact
U.S. Colorectal Cancer Markets - Patient Outlook
Dealmaking and Industry Outlook: Targeted Cancer Therapies
Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine
Global Biopharma Outlook 2012 - Major US and EU Pharma
Global Colorectal Cancer Drug Pipeline Capsule - 2012
U.S. Breast Cancer Therapeutics Markets
Colorectal Cancer (CRC) Therapeutics - Global Strategic Business Report
|
|
|
|
